The cost of pregnancy medication varies depending on the brand, dosage, and quantity ordered. Prices can also be notified using the monthly Special Price Promotion section.
The price for a 150 mg injection of medroxyprogesterone acetate in Pakistan is Rs 999.95. This is a brand name for the generic medication Depo-Provera. It is available in Pakistan in the form of 150 mg injections. This medicine is used to prevent pregnancy in women who are either pregnant or planning a pregnancy. It is also used for hormonal contraception. It can also be prescribed as a contraceptive if the mother or a relative has a history of pregnancy problems.
The price of this medicine in Pakistan varies depending on the pharmacy and whether it is a government-approved or privately funded medication. It is usually available in both branded and generic versions. The price for a 150 mg injection of medroxyprogesterone acetate in Pakistan is Rs 699.95. It is available in the form of 150 mg injections.
The cost of this medication varies depending on the brand, dosage, and quantity ordered. Prices can also be notified using the monthly Special Price Promises section. Visit the official price section of the Pakistan Health Information Products. Also, you can contact us for more information about the price and shipping.
PALABASA DRUG List (PALAVA)PALAVA is a drug combination manufactured by Centurion Laboratories. It is a combination of two drugs: provera medroxyprogesterone acetate (a progestin hormone) and depo-provera medroxyprogesterone acetate (a progestin). This drug combination is used to prevent pregnancy and to decrease the chance of getting a late miscarriage.
Each of the two drugs contains two active ingredients: medroxyprogesterone acetate and progesterone. This drug combination is known as a progestin and is used to prevent pregnancy. The two active ingredients are progesterone and medroxyprogesterone acetate.
The price for this medicine in Pakistan is Rs 699.95. This is a brand name for the generic medroxyprogesterone acetate. This medication is available in the form of 150 mg injections. This drug combination is manufactured by Centurion Laboratories. It is a combination of two active ingredients: medroxyprogesterone acetate and progesterone.
TENDODARD TABLETTendodart is used to treat osteoporosis in women who have a uterus. It is also used to prevent pregnancy after the first trimester. This drug combination is available in the form of tablets, capsules, and injectables. This drug combination is used to prevent pregnancy in women who are pregnant or planning a pregnancy. It may also be used for other purposes.
TENDODARD TOBY TABLETThe price of this medicine in Pakistan varies depending on the brand and dosage. The brand name of this medicine is medroxyprogesterone acetate.
PALAVA DosePALAVA is a tablet used to treat osteoporosis in women who have a uterus.
Depo-Provera Injection is used as a contraceptive to prevent pregnancy. Administered every three months, it contains medroxyprogesterone acetate, a progestin hormone that prevents ovulation, thickens cervical mucus, and thins the uterine lining, reducing the likelihood of fertilization and implantation. This method of birth control is suitable for women seeking long-term contraception without daily pills. Besides pregnancy prevention, it may be prescribed to manage menstrual disorders and reduce endometriosis-related pain. Regular medical monitoring is recommended to manage potential side effects and ensure ongoing suitability.
Depo-Provera Injection by Pfizer is a leading contraceptive solution offering significant convenience and efficacy for women seeking long-term birth control. Each single-dose vial contains 150 mg/mL of medroxyprogesterone acetate, designed for intramuscular administration. With a regimen requiring administration once every three months, Depo-Provera stands as a highly effective and low-maintenance option for those focused on long-term contraceptive needs. Packaged in trays of 25 vials, it is ideal for medical practices and healthcare institutions aiming to provide comprehensive contraceptive care to their patients.
Product Details and Features:
Active Ingredient:Each vial contains 150 mg/mL of medroxyprogesterone acetate, a progestin with potent contraceptive properties.Packaging:Supplied in trays with 25 single-dose vials, facilitating storage and distribution for healthcare providers.Indications:Primarily indicated for the prevention of pregnancy, Depo-Provera is well-suited for individuals preferring an injectable form of contraception.Administration Frequency:Requires administration once every three months, offering highly reliable, uninterrupted protection against pregnancy when used as directed.Quality Assurance:Manufactured by Pfizer, a global leader in pharmaceuticals, ensuring stringent quality control and consistent product performance.
Mechanism of Action:
Depo-Provera works by inhibiting the secretion of gonadotropins from the pituitary gland. This suppression prevents ovulation by halting the maturation of ovarian follicles. Additionally, it induces changes in the cervical mucus, making it thicker and less permeable to sperm. Finally, Depo-Provera alters the endometrial lining to discourage implantation. Together, these effects ensure a highly effective multifunctional approach to preventing pregnancy.
Warnings:
Side Effects:
Common side effects can include:
Serious side effects requiring medical attention include:
Conclusion:
Depo-Provera 150 mg/mL Single-Dose Vials, provided by Pfizer, offer a trusted, highly effective contraceptive option balancing convenience and reliability for long-term birth control. With a proven track record and the backing of Pfizer’s rigorous quality standards, it represents an ideal choice for those seeking dependable contraceptive care. Always buy from reputable sources to ensure your health is always as safe and effective as possible. Shop today at trusted pharmacies near you.
The European Union has approved a contraceptive injection for adolescents aged 13-18.
The European Committee for Medicinal Products (ECMP) on Tuesday said it was recommending the injection contain a hormone-progestogen mixture, which is similar to a hormone injection.
The European Committee for Medicinal Products (ECMP) said it was recommending the injection contain a hormone-progestogen mixture.
The committee advised that the injectable hormone-progestogen mixture can be used for adolescents aged 13-18.
The recommendation was made after a report by the Committee for Medicinal Products on the approval of hormone-progestone-only contraceptive injections for adolescents, which is indicated by a hormone-progestogen mixture, was published.
The Committee for Medicinal Products (CPP) recommended the injection be used under conditions and the injections administered through the nose.
The committee said that a progestogen-only injection, which is also indicated as a contraceptive, is not recommended.
In March, the Committee for Medicinal Products advised that the injection should be administered under conditions to protect against sexually transmitted infections (STIs), including gonorrhoea.
The Committee on Medical Products said that the injection is not recommended in adolescents aged 13-18.
The injection is also indicated for use in pregnant women who are at least 24 weeks pregnant.
The European Commission said that the European Committee on Human Medicinal Products (ECMP) had requested the injection for adolescents aged 13-18.The Committee for Medicinal Products (CPP) recommended that the injection should be administered under conditions to protect against sexually transmitted infections (STIs), including gonorrhoea. The injections are to be used by adolescents who are at least 24 weeks pregnant.
The Committee on Medical Products (CPP) said that the injection should be administered by the same route as the contraceptive injection and that the injection should be administered by the same route as the contraceptive injection.
The Committee on Medical Products (CPP) recommended that the injection should be administered by the same route as the contraceptive injection and that the injection should be administered by the same route as the contraceptive injection.
The European Commission had requested the injection for adolescents aged 13-18.
The Committee on Medical Products (CPP) recommended that the injection should be administered under conditions to protect against sexually transmitted infections (STIs), including gonorrhoea.
The European Commission on Tuesday said that the European Commission on Wednesday had requested the injection for adolescents aged 13-18.
The European Commission has also requested the injection for adolescents aged 13-18.
HIV remains a major global public health problem, particularly in developing countries. Despite advances in treatment, HIV-infected patients continue to experience significant and often irreversible complications, including the development of new antiretroviral therapies (ARMs). In response to the increasing incidence of HIV-infected patients in Europe, healthcare providers in Europe have increasingly started to prescribe injectable HIV drugs. This shift, together with a rise in the use of non-drug-based ARMs and the availability of generic ARMs, has contributed to the rise in the global HIV infection prevalence, which continues to increase worldwide. As a result, the World Health Organization estimates that global HIV infection prevalence is approximately 1.3% of adults.
Currently, only three HIV drugs are available in Europe, each with a corresponding high risk of mortality. One such drug, injectable dextrocycline (Depo-Provera), has been shown to increase the risk of death from the HIV infection and has been approved by the European Medicines Agency (EMA) to prevent HIV in low- and middle-income countries (LMICs). The efficacy of Depo-Provera in reducing the mortality rate of HIV-infected patients was demonstrated by the AEM/HIV-BID trial in combination with another HIV-drug (dextrocycline) in a large population-based cohort study (N=16,924), which showed that Depo-Provera reduced the mortality rate of HIV-infected patients in a dose-related manner with a similar reduction in mortality rates among patients who did not receive a combined HIV/dextrocycline regimen. Furthermore, Depo-Provera has been shown to reduce the incidence of HIV infection and mortality from HIV-infected patients with a high HIV-risk. The AEM/HIV-BID study has provided new evidence regarding the efficacy of Depo-Provera, in addition to a broader indication that it is the first injectable HIV drug approved in Europe.
In recent years, the availability of generic ARMs has contributed to the rise in the global HIV infection prevalence, which continues to increase worldwide. In Europe, for example, only two ARMs have been approved by the EMA for the treatment of HIV infection: mupirocin (Nexplanon, Pfizer) and vedolizumab (Viracept). Both are available in Europe, but both are not FDA-approved for HIV infection. Vedolizumab is an oral anti-viral medication that has been shown to decrease the incidence of HIV infection. The data in this study provide additional evidence to support the effectiveness of Vedolizumab in preventing HIV infection.
HIV is a leading cause of morbidity and mortality in Europe and is the most widely prescribed drug for this condition. A significant proportion of cases of HIV infection are acquired in the first trimester of gestation (the second or third trimester of pregnancy), with the incidence of HIV-related neonatal infections reaching approximately 40% of the population (1,100 cases per 100,000 live births). In addition, HIV-infected women are at increased risk of death during pregnancy, and women who are HIV-negative tend to be more likely to become pregnant or to experience complications from HIV infection. This increasing incidence of HIV infection in the last decade has been attributed to the development of antiretroviral therapies (ARTs) that target the viral DNA (drugs that have the capacity to reverse HIV infection) in a manner that reduces HIV-related mortality and increases the risk of neonatal mortality.
In this context, we have conducted a systematic review of the available data on the efficacy and safety of Vedolizumab in the management of HIV infection in Europe. Our findings support the evidence base for the use of Vedolizumab in the treatment of HIV infection and show that it can significantly reduce the mortality from this disease.
In this review, we examined the available data on the efficacy of Vedolizumab in the treatment of HIV infection in Europe. The review also examined the clinical impact of Vedolizumab on the treatment of HIV infection in the UK. The clinical impact of Vedolizumab was assessed by the UK National Health Service (NHS), which had a high proportion of patients with HIV infection. A systematic review was conducted to assess the impact of Vedolizumab on the treatment of HIV infection in the UK.
Stade de France Pharmacy